Melphalan‐flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma

Background: Chemotherapy options in advanced urothelial carcinoma (UC) remain limited. Here we evaluated the peptide‐based alkylating agent melphalan‐flufenamide (mel‐flufen) for UC. Methods: UC cell lines J82, RT4, TCCsup and 5637 were treated with mel‐flufen, alone or combined with cisplatin, gemc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Oncol
Autori principali: Viktorsson, Kristina, Shah, Carl-Henrik, Juntti, Therese, Hååg, Petra, Zielinska-Chomej, Katarzyna, Sierakowiak, Adam, Holmsten, Karin, Tu, Jessica, Spira, Jack, Kanter, Lena, Lewensohn, Rolf, Ullén, Anders
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2016
Soggetti:
Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423156/
https://ncbi.nlm.nih.gov/pubmed/26827254
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2015.12.013
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi